Canada Spends Logo

Explore our Budget 2026 analysis

Grant: TG: Biomedical Res. for HIV/AIDS/STBBI-Next-Gen.Therapeutic Interv.-Large Team

University of Calgary

$3,749,969.00

Pathways to Functional Cure in Chronic Hepatitis B

FY 2024-25

Summary
The hepatitis B virus (HBV) is a major cause of liver disease and liver cancer worldwide. Most people missed getting the vaccine and acquire the virus as infants or young children. Due to the young age of exposure, their immune system does not recognize the virus, they are unable to clear infection and develop "chronic hepatitis B" (CHB). The HBV hides inside the liver life-long and some can develop severe liver disease and liver scarring (i.e., cirrhosis). However, a very small number of people (one out of every 100 with CHB), for unclear reasons, are able to successfully clear the HBV such that it is no longer detectable using clinical tests. These people do not need treatment and have achieved a so called "functional cure". Expanding functional cure to the other 99% of individuals is urgently needed because it reduces the risk of liver disease and eliminates the need for life-long expensive treatment. In this study, we will enroll individuals who have achieved a functional cure and compare them to people who still have chronic hepatitis B. We will analyze their blood and liver immune cells for special markers that will help us understand why some (i.e., only 1/100) achieve functional cure. We will combine this data with clinical information and, using standard research methods and artificial intelligence (AI) approaches, find out how the body controls HBV. Finally, we will use liver cells grown in a lab dish, as well as woodchucks infected with a closely related virus (woodchuck hepatitis virus), to understand what factors inside the liver cell can help clear the virus. Identification of these factors can be used to develop improved treatments for hepatitis B. Our team includes experts in hepatitis B, liver and infectious disease specialists, veterinarians, scientists, artificial intelligence experts, patients and community partners that not only help achieve project goals but have enormous potential to advance understanding and care of HBV infection.
Program
TG: Biomedical Res. for HIV/AIDS/STBBI-Next-Gen.Therapeutic Interv.-Large Team
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
520510
Name
Coffin Carla S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Team Grant: Biomedical Research for HIV/AIDS and STBBI
Projecttitle
Pathways to Functional Cure in Chronic Hepatitis B
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$3,749,969
Cihrequipment2
$0
Programname2
TG: Biomedical Res. for HIV/AIDS/STBBI-Next-Gen.Therapeutic Interv.-Large Team
Keyworddelim
Artificial Intelligence (Ai); Flow Cytometry; Functional Cure (Fc); Hepatitis B Virus (Hbv); Human Immunology; Humanized Mouse Liver Model; Liver Disease; Novel Biomarkers; Single Cell Rna Sequencing (Scrnaseq); Woodchuck Hepatitis Virus (Whv) Model
Abstract
The hepatitis B virus (HBV) is a major cause of liver disease and liver cancer worldwide. Most people missed getting the vaccine and acquire the virus as infants or young children. Due to the young age of exposure, their immune system does not recognize the virus, they are unable to clear infection and develop "chronic hepatitis B" (CHB). The HBV hides inside the liver life-long and some can develop severe liver disease and liver scarring (i.e., cirrhosis). However, a very small number of people (one out of every 100 with CHB), for unclear reasons, are able to successfully clear the HBV such that it is no longer detectable using clinical tests. These people do not need treatment and have achieved a so called "functional cure". Expanding functional cure to the other 99% of individuals is urgently needed because it reduces the risk of liver disease and eliminates the need for life-long expensive treatment. In this study, we will enroll individuals who have achieved a functional cure and compare them to people who still have chronic hepatitis B. We will analyze their blood and liver immune cells for special markers that will help us understand why some (i.e., only 1/100) achieve functional cure. We will combine this data with clinical information and, using standard research methods and artificial intelligence (AI) approaches, find out how the body controls HBV. Finally, we will use liver cells grown in a lab dish, as well as woodchucks infected with a closely related virus (woodchuck hepatitis virus), to understand what factors inside the liver cell can help clear the virus. Identification of these factors can be used to develop improved treatments for hepatitis B. Our team includes experts in hepatitis B, liver and infectious disease specialists, veterinarians, scientists, artificial intelligence experts, patients and community partners that not only help achieve project goals but have enormous potential to advance understanding and care of HBV infection.
Competitiondate
202409
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Coffin, Carla S; Ko, Hin Hin; Cooper, Curtis L; Crawley, Angela M; Gehring, Adam J; Jenne, Craig N; Meier-Stephenson, Vanessa
Approvedterm
5 ans 0 mois
Cihrcontribution2
MI #3~ $3,749,969~ $0~